Home Alzheimer’s Disease FDA Approves Cemiplimab as First Immunotherapy to Treat Patients With Advanced BCC

FDA Approves Cemiplimab as First Immunotherapy to Treat Patients With Advanced BCC

Cemiplimab (Libtayo) is now approved by the FDA to treat patients with basal cell carcinoma (BCC) following treatment with a hedgehog pathway inhibitor (HHI) or for whom these therapies are not appropriate, according to Regeneron Pharmaceuticals and Sanofi – the drug’s manufacturers.

The fully human monoclonal antibody targeting PD-1 is approved at the recommended dose of 350 mg administered as an intravenous infusion over 30 minutes every 3 weeks until disease progression or unacceptable toxicity.

“Today’s FDA approval of Libtayo will change the treatment paradigm for patients with advanced basal cell carcinoma,’ Karl Lewis, MD, professor in the Division of Medical Oncology at the University of Colorado as well as a trial investigator, said in a press release. “Advanced basal cell carcinoma is a persistent, painful, and highly disfiguring cancer. While the primary…

Continue Reading to the Source


Please enter your comment!
Please enter your name here

Most Popular

Robert J. Motzer, MD, on Outcomes of the Phase 3 CheckMate 9ER Trial in Advanced RCC

According to results of a subgroup analysis from the phase 3 CheckMate 9ER trial (NCT03141177) presented at the American Society of Clinical Oncology (ASCO)...

Patients Aged 70 or Older With Esophageal or EGJ Cancers Should Be Evaluated for Optimal Curative Therapy

Older patients with locoregional esophageal or esophagogastric junction (EGJ) cancer need to be evaluated for optimal curative therapy, including neoadjuvant chemoradiotherapy and surgical resection,...

Third COVID-19 Vaccine Earns Emergency Use Authorization Following Favorable Advisory Committee Meeting

The first single-dose COVID-19 vaccine was granted Emergency Use Authorization (EUA) by the FDA, according to its developer Janssen Pharmaceutical Companies of Johnson &...

Abiraterone Acetate, Apalutamide Likeliest to Improve Survival for Patients with Castration-Sensitive Prostate Cancer

In a comparison of systemic treatments as add-ons to androgen-deprivation therapy (ADT) for patients with metastatic castration-sensitive prostate cancer (mCSPC), abiraterone acetate (Zytiga) and...

Recent Comments